News | February 03, 2008

CMS Favors Reimbursement for CardioWest Artificial Heart

February 4, 2008 - The Centers for Medicare & Medicaid Services (CMS) announced that after completing a review of its 1986 national non-coverage policy for artificial hearts, its preliminary decision is to provide reimbursement for patients who receive the CardioWest temporary Total Artificial Heart (TAH-t) as part of FDA studies that meet CMS specifications.

Following a public comment period, CMS will post its final decision on May 1, 2008. "Our proposal relaxes a long-standing non-coverage policy, gives access to our beneficiaries and promotes evidence development through FDA approved studies of this advanced technology," said CMS Acting Administrator Kerry Weems. "This device may be able to help patients that otherwise have no treatment options available to them."

"This decision is a historic step toward making the artificial heart available to most Americans," explained Rodger Ford, president and CEO of SynCardia Systems, Inc., manufacturer of the CardioWest artificial heart. "Many smaller insurers use CMS reimbursement decisions as their benchmark for coverage."

The CardioWest artificial heart is currently covered by about half of insurers, including Aetna and BlueCross BlueShield. With final CMS approval, most insurers are likely to cover the CardioWest artificial heart.

On Aug. 1, 2007, CMS posted a notice to its website announcing the review of this non-coverage policy, after SynCardia submitted a formal request for coverage of the CardioWest artificial heart when used in accordance with its FDA-approved labeling as a bridge to human heart transplant.

The CardioWest artificial heart received FDA approval on Oct. 15, 2004. It is the world�s only FDA, CE and Health Canada approved temporary total artificial heart. It has been implanted in more than 700 patients, accounting for more than 120 patient years of life on the device.

For more information: www.cardiowest.com

Related Content

St. Jude Medical, HeartMate 3 LVAS, MOMENTUM 3 IDE study results, AHA Scientific Sessions 2016
News | Ventricular Assist Devices (VAD)| December 08, 2016
St. Jude Medical Inc. announced results of the MOMENTUM 3 U.S. IDE Clinical Study during a late-breaking clinical trial...
SynCardia, Chapter 11 reorganization, sale, Total Artificial Heart
News | Artificial Heart| September 13, 2016
August 29, 2016 — SynCardia Systems, manufacturer of the...
Carmat, bioprosthetic artificial heart, PIVOTAL study, first implantation, heart failure
News | Artificial Heart| September 09, 2016
Carmat announced that the first implantation of its bioprosthetic artificial heart within the framework of the PIVOTAL...
SynCardia acquired, Versa Capital Management, chapter 11
News | Business| July 07, 2016
SynCardia Systems Inc. announced that it has entered into an asset purchase agreement (“APA”) with an affiliate of...
SynCardia Total Artificial Heart, TAH-t, documentary, Retro Reports, The New York Times
News | Artificial Heart| March 24, 2016
March 24, 2016 — A new documentary produced by Retro Report for The New York Times looks at the history and
Bryan Tyo, Baylor University Medical Center, bridge to transplant, Total Artificial Heart
News | Artificial Heart| March 18, 2016
A surgical team at Baylor University Medical Center at Dallas successfully performed a heart transplant on a patient...
HeartWare, ENDURANCE2 trial, destination therapy, HVAS, HeartWare Ventricular Assist System
News | Ventricular Assist Devices (VAD)| August 11, 2015
HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been...
News | January 30, 2015
SynCardia Systems Inc. has received U.S. Food and Drug Administration (FDA) approval to conduct a clinical study of the...
syncardia, artificial heart

SynCardia Total Artificial Heart

News | November 24, 2014
A 19-year-old woman was successfully implanted with the SynCardia temporary Total Artificial Heart and bridged to a...
Overlay Init